Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study

Journal of Alzheimer's Disease

Volumn 45, Issue 3, 2015, Pages 771-780

  Matsuzono, Kosuke ^a   Hishikawa, Nozomi ^a   Ohta, Yasuyuki ^a   Yamashita, Toru ^a   Deguchi, Kentaro ^a   Nakano, Yumiko ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; combination therapy; donepezil; galantamine; memantine

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME; COHORT ANALYSIS; DOSE RESPONSE; DRUG COMBINATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GALANTAMINE; HUMANS; INDANS; JAPAN; MALE; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 84925813459     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-143084     Document Type: Article

References (28)

1. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, AD Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 363, 2105-2115.
2. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397.
3. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK; American College of Physicians/American Academy of Family Physicians Panel on Dementia (2008) Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 148, 370-378.
4. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study, Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
5. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21, 1317-1327.
6. Nakamura Y, Imai Y, Shigeta M, Graf A, Shirahase T, Kim H, Fujii A, Mori J, Homma A (2011) A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 1, 163-179.
7. Cummings JL1, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study, Group (2006) Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67, 57-63.
8. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22, 209-221.
9. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky STN (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80, 600-607.
10. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS (2009) Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1, 7.
11. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903.
12. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study, Group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324.
13. Riordan KC, Hoffman Snyder CR, Wellik KE, Caselli RJ, Wingerchuk DM, Demaerschalk BM (2011) Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: A critically appraised topic. Neurologist 17, 121-123.
14. Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Memantine MEM-MD-02 Study Group (2006) Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: An exploratory reanalysis. Alzheimer Dis Assoc Disord 20, 255-262.
15. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A (2000) Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 176, 68-73.
16. Ago Y, Koda K, Takuma K, Matsuda T (2011) Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 116, 6-17.
17. Spanagel R, Eilbacher B, Wilke R (1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmacokinetic microdialysis study. Eur J Pharmacol 262, 21-26.
18. Onogi H, Ishigaki S, Nakagawasai O, Arai-Kato Y, Arai Y, Watanabe H, Miyamoto A, Tan-no K, Tadano T (2009) Influence of memantine on brain monoaminergic neurotransmission parameters in mice: Neurochemical and behavioral study. Biol Pharm Bull 32, 850-855.
19. Hasselink MB, De Boer AG, Breimer DD, Danysz W (1999) Dopamine release in the prefrontal cortex in response to memantine following sub-chronic NMDA receptor blockade with memantine: A microdialysis study in rats. J Neural Transm 106, 803-818.
20. Wilcock GK, Ballard CG, Cooper JA, Loft H (2008) Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. J Clin Psychiatry 69, 341-348.
21. Gauthier S, Wirth Y, Mobius HJ (2005) Effects of memantine on behavioural symptoms in Alzheimer's disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20, 459-464.
22. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B; Donepezil MSAD Study Investigators Group (2002) Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 14, 389-404.
23. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J (2004) The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63, 214-219.
24. Tanaka T, Kazui H, Morihara T, Sadik G, Kudo T, Takeda M (2008) Post-marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer's disease with behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics 8, 114-123.
25. Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol 6, 782-792.
26. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S, American Heart Association Stroke Council, Council on Epidemiology, Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology, Intervention, Council on Cardiovascular Surgery Anesthesia (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 2672-2713.
27. Erkinjuntti T, Kurz A, Gauthier A, Bullock R, Lilienfeld S, Damaraju CV (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet 359, 1283-1290.
28. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group (2007) Galantamine treatment of vascular dementia: A randomized trial. Neurology 69, 448-458.